How Partnerships Work
Stage 1, scientific evaluation, Stage 2 where required, scope, agreement, activation, work, review and output pathways are explicit.
PUBLIC GOVERNANCE CENTER
This center separates organizational acceptance from journal acceptance, funding from authorship, microscopIA delivery from journal timelines, and public Stage-1 forms from restricted project workflows.
Policy version GLOBAL-PARTNERSHIPS-2026.09-v2 · effective 2026-09-20
SUBMISSION FORMS
GOVERNANCE AREAS
Stage 1, scientific evaluation, Stage 2 where required, scope, agreement, activation, work, review and output pathways are explicit.
Responsibilities, decisions, methods, source authority and project-specific oversight are defined before activation.
No ghostwriting, guaranteed outcomes, simultaneous journal submissions, purchased authorship or suppression of inconvenient findings.
Authorship follows qualifying scientific contribution, accountability and final approval. Funding never purchases authorship.
Employment, consultancy, honoraria, funding, grants, equity, ownership, patents, advisory and relevant relationships are disclosed.
Journal suitability, indexing, authorship, corresponding-author eligibility and a legitimate access route are confirmed before submission.
Preferential pricing is determined by primary institutional affiliation only and never changes scientific, authorship or editorial standards.
Source-data owners retain ownership/control unless contractually changed. Public forms never collect patient identifiers or restricted research files.
Support does not automatically confer authorship, scientific control, suppression rights, ownership of results or control over conclusions.
AI, device, software, patentable and commercial innovation requires project-specific background IP, inventorship, ownership, licensing and publication terms.
Material differences in data, cleaning, objectives, endpoints, workstreams, authors, regulation or prospective collection trigger formal re-scoping.
PROJECT STATE MODEL
A publication partnership uses explicit states so each stakeholder can distinguish evaluation, activation, scientific work and independent journal decisions.
PUBLICATION & OPEN ACCESS POLICY
Selected PubMed-indexed journals that are scientifically appropriate for the work
microscopIA-funded open access applies only when a qualifying microscopIA author legitimately serves as corresponding author. Funding does not purchase authorship.
When another legitimate corresponding-author arrangement applies, microscopIA ordinarily uses a subscription route where the selected journal offers one.
If a journal is fully open access and the project does not meet the open-access eligibility rule, the team must choose another eligible journal or legitimate arrangement before submission.
Publisher arrangements are separate, dated, governed and agreement-specific. Portfolio naming never guarantees that every journal or article is eligible. When an eligible article-processing charge is funded, direct payment to the publisher is preferred. The public planner never adds an imaginary APC.
Never guaranteed: authorship, journal acceptance, publication, indexing, editorial outcome, citation impact, regulatory or policy adoption.
EXTERNAL STANDARDS
These references guide relevant controls; they do not imply certification, accreditation, journal endorsement or a substitute for project-specific legal, ethics or institutional review.
WCAG 2.2 Level AA is the active design and testing target, not an unverified conformance certification.
W3C WCAG 2.2 ↗Qualifying authors are expected to satisfy all four ICMJE authorship criteria; other contributions should be acknowledged transparently.
ICMJE authorship guidance ↗COPE process guidance informs authorship and publication-ethics workflows, subject to the controlling journal and institutional requirements.
COPE authorship discussion document ↗World Bank FY2027 is the versioned source for non-regional income tiers. Latin America & Caribbean access is a separate microscopIA policy.
World Bank country and lending groups ↗REGIONAL ACCESS PRICING
Permanent regional baseline
The primary institutional affiliations of the proposed external authors—not nationality, citizenship, residence, ethnicity or personal identity.
The Colombia baseline applies when strictly more than 50% of the external team has a primary institutional affiliation in Colombia. Otherwise, the Latin America & Caribbean baseline applies when strictly more than 50% of the external team has a primary institutional affiliation in the region. Exactly 50% or no majority requires individual evaluation.
Regional pricing does not change scientific evaluation, authorship criteria, peer-review independence, journal selection, publication standards or editorial outcomes.
The Americas promotion applies to current project fees for projects approved by October 31, 2026, at 11:59 p.m. Colombia time, thanks to Dr. Agamenón Quintero Villarreal. It excludes the United States and Canada, taxes and third-party charges. Other promotional reductions do not combine with it.
TWO SEPARATE CLOCKS
Standard, accelerated and preferential targets are up to 8, 4 and 2 weeks after complete Project Activation for microscopIA’s submission-ready scientific work. Editorial screening, peer review, revision, acceptance, production, indexing and publication remain independently controlled by the journal or publisher and have no promised duration.
ACTIVATION PACKAGE
These records are issued through the active project workflow; they are not public acquisition forms.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
Project-specific route after acceptance.
DATABASE READINESS
Original research requires organized structure, clear coding, a data dictionary or codebook, defined missing values, variable definitions, reasonable internal consistency, controlled duplication and appropriate de-identification.
RESEARCH ETHICS
At Stage 1, microscopIA asks only whether the required consent or approvals are obtained, not for patient names, signatures or source documents. Actual consent remains under institutional custody; project-specific verification and secure transfer occur only after qualification or activation.
EVIDENCE ATTRIBUTION
microscopIA initiates or conducts the project using its scientific network and retains primary scientific governance.
Work is conducted jointly with external investigators, institutions or partners.
Work belongs to a network participant but was produced independently, without microscopIA affiliation, governance or substantive participation. It is never counted as microscopIA-produced evidence.
LEGACY COMMERCIAL TRANSITION
Network participation is not the commercial product. No Associate, Senior, monthly or subscription offer is sold, and network status is not required to submit, collaborate or publish.
The preserved 30% reduction applies for 12 months measured from the individual eligibility date recorded in the controlling terms. No new paid membership or transition entitlement is sold.
WHAT HAPPENS IF?
microscopIA acceptance approves a project for scope and activation. Journal acceptance is a later, independent editorial decision.
No. Nothing is payable for a Stage-1 submission or simulation. An Activation Payment becomes due only after microscopIA acceptance and under the executed terms.
No. Payment never confers authorship. Open-access eligibility depends on the legitimate corresponding-author arrangement and the selected journal or publisher agreement. No editorial outcome is guaranteed.
The external institution or investigators retain ownership/control unless a specific contract says otherwise. microscopIA receives only the rights required for the agreed work; unrelated secondary use requires authorization.
No automatic scientific, statistical or suppression rights arise from support. Commercially sponsored projects may negotiate IP and publication terms while preserving scientific integrity and required disclosures.
No. Support, funding, scientific contribution or institutional sponsorship language is used until the receiving entity and jurisdiction have appropriate legal/accounting confirmation.